Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chel Hun Choi

Showing results (301-310 of 309) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 309 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
The Journal of Obstetrics and Gynaecology Research|December 10, 2019
Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter studySe Ik Kim, Chel Hun Choi, Kidong Kim, et al.
The Lancet. Oncology|January 18, 2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trialNatalie Y L Ngoi, Jung-Yun Lee, Diana Lim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
Cancers|October 16, 2024
From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next StepsKyung-Jin Min, Nam Kyeong Kim, Jae-Yun Song, et al.
Journal of Gynecologic Oncology|February 8, 2024
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)Bo Seong Yun, Kwang-Beom Lee, Keun Ho Lee, et al.
Genome Biology|November 28, 2019
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancersJason K Sa, Jae Ryoung Hwang, Young-Jae Cho, et al.
Pageof 31

Showing results (301-310 of 309) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 309 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
The Journal of Obstetrics and Gynaecology Research|December 10, 2019
Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter studySe Ik Kim, Chel Hun Choi, Kidong Kim, et al.
The Lancet. Oncology|January 18, 2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trialNatalie Y L Ngoi, Jung-Yun Lee, Diana Lim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
Cancers|October 16, 2024
From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next StepsKyung-Jin Min, Nam Kyeong Kim, Jae-Yun Song, et al.
Journal of Gynecologic Oncology|February 8, 2024
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)Bo Seong Yun, Kwang-Beom Lee, Keun Ho Lee, et al.
Genome Biology|November 28, 2019
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancersJason K Sa, Jae Ryoung Hwang, Young-Jae Cho, et al.
Pageof 31